within Pharmacolibrary.Drugs.ATC.N;

model N03AB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.02 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Ethotoin is a hydantoin anticonvulsant that was historically used to treat epilepsy and prevent seizures, particularly in cases of generalized tonic-clonic (grand mal) and complex partial seizures. Its use has largely been discontinued or replaced by other antiepileptic drugs due to its lower efficacy and safety concerns, and it is not widely approved or marketed today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult patients following oral administration, as no primary pharmacokinetic studies with reported parameters in existing literature were found.</p><h4>References</h4><ol><li><p>Hooper, WD, et al., &amp; Qing, MS (1992). Enantioselective pharmacokinetics of ethotoin in humans following single oral doses of the racemate. <i>Chirality</i> 4(3) 142â€“147. DOI:<a href=&quot;https://doi.org/10.1002/chir.530040303&quot;>10.1002/chir.530040303</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1350205/&quot;>https://pubmed.ncbi.nlm.nih.gov/1350205</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N03AB01;
